

MATERIAL CHANGE REPORT

PURSUANT TO SECTION 7.1 OF NATIONAL INSTRUMENT 51-102

1. **Name and Address of Company:**

Miraculins Inc. (the "Company")
6 – 1250 Waverley Street
Winnipeg, Manitoba R3T 6C6

2. **Date of Material Change:**

December 6, 2011

3. **News Release:**

The Company issued a press release regarding the material change on December 6, 2011, a copy of which is attached hereto.

4. **Summary of Material Change:**

Miraculins announces internationally renowned cardiologist Dr. G.B. John Mancini, MD, FRCPC, FACC, Vancouver Coastal Health Research Institute – University of British Columbia, has been appointed Chair of the PreVu Medical Advisory Board.

5. **Full Description Of Material Change:**

See attached Schedule "A".

6. **Reliance on subsection 7.1(2) or (3) of National Instrument 51-102:**

Not Applicable.

7. **Omitted Information:**

Not Applicable.

8. **Executive Officer:**

Christopher Moreau, Chief Executive Officer
Tel: (204) 453-1408

DATED at Winnipeg, Manitoba this 9th day of December, 2011.

MIRACULINS INC.

Per: "Christopher Moreau"
Chris Moreau
President & CEO

SCHEDULE "A"

Miraculins Appoints Leading Cardiologist Dr. G. B. John Mancini as Chair of the PreVu Medical Advisory Board

WINNIPEG, Manitoba – December 6, 2011 - Miraculins Inc. (TSX-V:MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, announces that internationally renowned cardiologist Dr. G.B. John Mancini, MD, FRCPC, FACC, Vancouver Coastal Health Research Institute – University of British Columbia, has been appointed Chair of the PreVu Medical Advisory Board.

Dr. Mancini has been a dedicated clinician scientist in the field of cardiology for over three decades with a specific focus on cardiovascular imaging. As founder and director of the highly respected Cardiovascular Imaging Research Core Laboratory (CIRCL), Dr. Mancini has overseen CIRCL through numerous multi-centre clinical trials providing quantitative image analysis for thousands of patients – including the notable multi-centre studies COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluations) and OAT (Occluded Artery Trial). He has more than 195 publications to his credit and has made tremendous contributions to the understanding of coronary artery disease throughout his distinguished career.

In 2002, Dr. Mancini and colleagues at the University of British Columbia, examined the association between Skin Cholesterol, markers of inflammation and conventional lipid parameters. They found that Skin Cholesterol had significant and positive correlations with systolic blood pressure, LDL-C and the Framingham Coronary Artery Disease (CAD) risk calculation model. They also found that Skin Cholesterol significantly correlated with one major marker for inflammation and approached significance with high-sensitivity C-reactive protein (hs-CRP) and two other indicators of systemic inflammation. This is especially important because of what is now known about the critically important relationship between chronic inflammation and the risk of unstable (vulnerable) coronary plaque. The study was published in the prestigious peer reviewed publication *The American Journal of Cardiology*.

"I am very pleased to be chairing the PreVu Medical Advisory Board," said Dr. Mancini. "Skin cholesterol is an exciting new biomarker that can help aid in the early detection of Coronary Artery Disease (CAD) risk. PreVu's core value rests in its ability to uncover individuals with hidden, high levels of risk for treatment that are currently not being identified by traditional biomarkers and screening methods and that is where we must redouble our clinical efforts. I look forward to working with Miraculins to help ensure the successful use of the non-invasive PreVu test, educating the public and health care professionals about the science behind this new element for risk assessment and its important role in the early detection of CAD."

"Dr. Mancini is regarded as an internationally renowned expert in the use of novel diagnostic tools to assess cardiovascular health and is a highly sought-out researcher and clinical lecturer", said Christopher J. Moreau President and CEO of Miraculins. "I am very pleased with his decision to accept the role of Chair of the PreVu Medical Advisory Board and I look forward to working with him closely on the upcoming PreVu Launch."

About Dr. G. B. John Mancini

Dr. Mancini continues to be at the forefront of the latest medical imaging technologies. He holds Level 3 Certification in Cardiac Computed Tomography, is a Diplomate of the Certification Board in Cardiac Computed Tomography and was one of a small group of practitioners of cardiac computed tomography to have helped to author the first Canadian guidelines for the use of this new technology in clinical practice. Dr. Mancini's professional memberships include the Society of Cardiovascular Computed Tomography and the editorial boards of *The American Journal of Cardiology*, *The Canadian Journal of Cardiology*, *Clinical and Investigative Medicine*, and *the Journal of the American College of Cardiology*. He is also a member of the Scientific Review Committee for the Heart and

Stroke Foundation of Canada.

About The PreVu Non-Invasive Skin Cholesterol Test

PreVu is a non-invasive risk assessment technology that evaluates the additional risk a person may have for coronary artery disease (CAD) by conveniently and painlessly testing their skin cholesterol level. High levels of skin cholesterol have been shown to be correlated to CAD as measured by stress test, angiography, coronary calcium, and carotid intima-media thickness, inflammatory markers of vascular disease, previous heart attack incidents and Framingham risk score.

About Miraculins Inc.

Miraculins is a medical diagnostic development company focused on acquiring and advancing non-invasive tests for unmet clinical needs. The Company's PreVu test is a revolutionary new coronary artery disease (CAD) risk assessment technology that measures cholesterol levels in a patient's skin non-invasively, painlessly and without the need for fasting. PreVu has previously been successfully test marketed in North America on a limited basis. Miraculins additional programs include a research use only ELISA kit for the detection of PSP94; and a suite of biomarkers to aid in the early detection of the devastating disease of pregnancy known as preeclampsia. The Company's preeclampsia program is being advanced in partnership with Alere, Inc. (NYSE:ALR) (formerly known as Inverness Medical Innovations), one of the world's largest diagnostic companies. For more information on Miraculins please visit www.miraculins.com. PreVu Non-Invasive Cholesterol Test technology is not currently licensed for sale in Canada.

For more information, please contact:

Christopher J. Moreau
President and CEO
Miraculins Inc.
Ph: 204-477-7599
Fax: 204-453-1546
info@miraculins.com
www.miraculins.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, "forward-looking statements"). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.

These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: Miraculins' early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers' willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in Miraculins' filings with Canadian securities regulatory authorities, as well as Miraculins' ability to anticipate and manage the risks associated with the foregoing. Additional information about these factors and about the material factors or assumptions underlying

such forward-looking statements may be found in the body of this news release. Miraculins cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on Miraculins' forward-looking statements to make decisions with respect to Miraculins investors and others should carefully consider the foregoing factors and other uncertainties and potential events.

These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Miraculins cannot provide assurance that actual results will be consistent with these forward-looking statements. Miraculins undertakes no obligation to update or revise any forward-looking statement.

® PreVu is a registered trademark of Miraculins Inc. All Rights Reserved. 2011.